

Educational Session

Tuesday, Aug. 31

Room A

Time: 8:00-8:10

Opening Remarks

Takashi Nakano, Conference Chair IMIG 2010
(Hyogo College of Medicine, Japan)

Time: 8:10-8:35

The mesothelial cell

Chair: Shotaro Maeda
(Tama-Nagayama Hospital, Nippon Medical School, Japan)

ES01 The mesothelial cell

Steven Mutsaers
(Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research,
Department of Medicine, University of Western Australia, Australia)

Time: 8:35-9:00

Mechanisms of asbestos-induced carcinogenesis

Chair: Naohiko Inase
(Tokyo Medical and Dental University, Japan)

ES02 Mechanisms of asbestos-induced carcinogenesis

Marie-Claude Jaurand
(INSERM, UMR U-674, IUH Université Paris Descartes, France)

Time: 9:00-9:25

Apoptosis and mesothelioma

Chair: Hirotohi Akita
(Hokkaido University Graduate School of Medicine, Japan)

ES03 Apoptosis and mesothelioma

Courtney Broaddus
(University of California, San Francisco, Chief, Division of Pulmonary and Critical Care
Medicine San Francisco General Hospital, USA)

Time: 9:25-9:50

New pathways for molecular targeted therapies

Chair: Kazuhisa Takahashi
(Juntendo University School of Medicine, Japan)

ES04 New pathways for molecular targeted therapies

Luciano Mutti
(Department of Medicine, Local Health Unit 11, Vercelli, Italy)

Time: 9:50-10:15

Clinically relevant chromosomal and molecular biomarkers in asbestos-related tumors

Chair: Yoshitaka Sekido

(Aichi Cancer Center, Hospital and Research Institute, Japan)

ES05 Clinically relevant chromosomal and molecular biomarkers in asbestos-related tumors

Sakari Knuutila

(Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland)

Time: 10:35-11:00

Clinical aspects of malignant pleural mesothelioma

Chair: Yoshirou Mochiduki

(National Hospital Organization Himeji Medical Center, Japan)

ES06 Clinical aspects of malignant pleural mesothelioma

Hugo Schouwink

(Department of Pulmonary Diseases Medisch Spectrum Twente, Enschede, The Netherlands)

Time: 11:00-11:25

Peritoneal mesothelioma-Clinical and translational research in pharmacology of cancer chemotherapy-

Chair: Eiji Shimizu

(Tottori University Faculty of Medicine, Japan)

ES07 Peritoneal mesothelioma – Clinical and translational research in pharmacology of cancer chemotherapy

Paul Sugarbaker

(Washington Cancer Institute, Washington, DC, USA)

Time: 11:25-11:50

Malignant Mesothelioma - new diagnostic tools

Chair: Hiroshi Niwa

(Seirei Mikatahara General Hospital, Japan)

ES08 Malignant mesothelioma – new diagnostic tools

Bruce Robinson

(National Centre for Asbestos Related Diseases, University of Western Australia, Australia)

Time: 13:00-13:25

Systemic therapy for mesothelioma: First and second-line treatment

Chair: Mikio Oka

(Kawasaki Medical School, Japan)

ES09 Systemic therapy for mesothelioma: First and second-line treatment

Hedy Kindler

(Section of Hematology/Oncology, University of Chicago, USA)

Time: 13:25-13:50

Palliative benefit of chemotherapy for mesothelioma

Chair: Yukito Ichinose
(National Kyushu Cancer Center, Japan)

ES10 Palliative benefit of chemotherapy for mesothelioma

Jeremy Steele
(Department of Medical Oncology, St Bartholomew's Hospital, UK)

Time: 13:50-14:15

Immunotherapy for mesothelioma

Chair: Yasuhiko Nishioka
(The University of Tokushima Graduate School, Japan)

ES11 Immunotherapy for mesothelioma

Steven Albelda
(Thoracic Oncology Gene Therapy Program, University of Pennsylvania Medical Center, USA)

Time: 14:15-14:40

Gene therapy for mesothelioma

Chair: Yoshinori Hasegawa
(Nagoya University Graduate School of Medicine, Japan)

ES12 Gene therapy for mesothelioma

Daniel Sterman
(Thoracic Oncology Gene Therapy Program, University of Pennsylvania Medical Center, USA)

Time: 15:00-15:25

TNM staging of malignant pleural mesothelioma

Chair: Shinichiro Miyoshi
(Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan)

ES13 TNM staging of malignant pleural mesothelioma

Valerie Rusch
(Thoracic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, USA)

Time: 15:25-15:50

Role of radical surgery within a multimodality concept

Chair: Hiroshi Date
(Graduate School of Medicine and Faculty of Medicine, Kyoto University, Japan)

ES14 Role of radical surgery within a multimodality concept

Walter Weder
(Division of Thoracic Surgery, University Hospital Zürich, Switzerland)

Time: 15:50-16:15

Overview of the surgical debate for pleural mesothelioma

Chair: Masahiro Tsuboi
(Kanagawa Cancer Center, Japan)

ES15 Overview of the surgical debate for pleural mesothelioma

Harvey Pass
(Division of Thoracic Surgery and Thoracic Oncology, Department of Cardiothoracic Surgery, NYU Langone Medical Center and Cancer Center, USA)

Time: 16:45-17:10

Multimodality treatment of MPM

Chair: Koichi Kaneko
(Saitama Medical University International Medical Center, Japan)

ES16 Multimodality treatment of MPM

Paul Baas
(Department of Thoracic Oncology, The Netherlands Cancer Institute, The Netherlands)

Time: 17:10-17:35

European guidelines for the treatment of malignant pleural mesothelioma

Chair: Meinoshin Okumura
(Osaka University Graduate School of Medicine, Japan)

ES17 European guidelines for the treatment of malignant pleural mesothelioma

Jan van Meerbeeck
(Department of Respiratory Medicine and Thoracic Oncology, Ghent University Hospital, Belgium)

Time: 17:35-18:00

Trends in mesothelioma incidence

Chair: Jim teWaterNaude
(Asbestos Relief Trust, South Africa and School of Public Health, University of Cape Town, South Africa)

ES18 Trends in mesothelioma incidence

Ken Takahashi
(Department of Environmental Epidemiology, University of Occupational and Environmental Health, Japan)

Room B1

Time: 13:00-13:40

Pathology Lecture-1 Advances in the pathology of malignant mesothelioma

Chair: **Yoshihiro Matsuno**
(Hokkaido University Hospital, Japan)

ES PL01 Advances in the pathology of malignant mesothelioma

Andrew Churg
(Department of Pathology, University of British Columbia, Canada)

Time: 13:40-14:20

Pathology Lecture-2 Cytological diagnosis for mesothelioma

Chair: **Françoise Galateau-Sallé**
(University of Caen, France)

ES PL02 Cytological diagnosis for mesothelioma

Toshiaki Kamei
(Division of Pathology, Yamaguchi Grand Medical Center, Japan)

Time: 15:00-15:40

Pathology Lecture-3 Verification of the consensus statement from the IMIG2006

Chair: **Yuichi Ishikawa**
(The Cancer Institute, Japanese Foundation for Cancer Research, Japan)

ES PL03 Verification of the consensus statement from IMIG 2006

Victor Roggli
(Department of Pathology, Duke University Medical Center, USA)

Time: 15:40-16:20

Pathology Lecture-4 Mesothelioma with special references to diagnostic accuracy

Chair: **Steven Mutsaers**
(University of Western Australia, Australia)

ES PL04 Mesothelioma with special references to diagnostic accuracy

Kouki Inai
(Division of Medical Intelligence and Informatics, Hiroshima University Graduate School of Biomedical Sciences, Japan)

Tuesday, Aug. 31

Room B1

Time: 16:45-18:00

Difficult Cases: Difficult cases: ask the expert

Chair: Toshiaki Kawai

(Department of Pathology and Laboratory Medicine, National Defense Medical College, Japan)

Chiho Ohbayashi

(Department of Pathology, Hyogo Cancer Center, Japan)

DC01-1 A calcified pleural tumour in a patient with asbestos exposure: Osteosarcoma or osteogenic sarcomatoid mesothelioma?

Clare Hooper

(Pleural Clinical Trials Unit, North Bristol Lung Centre, Southmead Hospital, UK)

DC01-2 Localized epithelial malignant mesothelioma

Gunnar Hillerdal

(Lung Department, Karolinska Hospital, Sweden)

DC01-3 Successfully treated stage III myxomatous epithelial mesothelioma presenting with a recurrent three liter mucinous pleural effusion

Joseph Friedberg

(Penn Mesothelioma and Pleural Disease Program Coordinator Thoracic Surgery Clinical Practice and Research Coordinator, USA)

DC01-4 20 year-old female with inhibin-positive epithelioid mesothelioma

Elad Sharon

(Medical Oncology Fellow, National Cancer Institute, USA)